November 18 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] said on Thursday its consolidated net profit rose 14% year-on-year to 240 million euro ($271.9 million) in the first nine months of 2021.
Krka's consolidated revenue increased 1% on the year to 1.177 billion euro in the nine months through September, the company said in a filing with the Ljubljana Stock Exchange.
Krka's consolidated EBITDA amounted to 352.7 million euro in the first nine months, down 8% year-on-year.
The Krka Group allocated 45.3 million euro to investments in January-September, of which 34.8 million euro to the controlling company.
The group employed 11,470 people at the end of September, down from 12,410 at the end of 2020.
Eastern Europe generated the highest sales within the group, of 397.7 million euro, or 33.9% of total sales. Next came Central Europe, where sales revenue came in at 271.9 million euro, or 23.2% of total sales. West Europe followed with sales of 229.0 million euro, 19.5% of total.
Sales in Southeast Europe amounted to 164.2 million euro, whereas sales in the Overseas Markets contributed 41.8 million euro. Sales in Slovenia stood at 68.8 million euro and generated 5.9% of total Krka group sales.
($ = 0.88275 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here